Literature DB >> 29787401

Melatonin Receptor Agonist Ramelteon Reduces Ischemia-Reperfusion Injury Through Activation of Mitochondrial Potassium Channels.

Martin Stroethoff1, Iris Christoph1, Friederike Behmenburg1, Annika Raupach1, Sebastian Bunte1, Semra Senpolat1, André Heinen2, Markus W Hollmann3, Alexander Mathes4, Ragnar Huhn1.   

Abstract

Activation of melatonin receptors induces cardioprotection. Mitochondrial potassium channels (mKCa and mKATP) are involved in the signaling cascade of preconditioning. The melatonin receptor agonist ramelteon is an approved oral medication for treatment of insomnia, but nothing is known about possible cardioprotective properties. We investigated whether (1) ramelteon induces cardioprotection mediated by the melatonin receptor; (2) this effect is concentration-dependent; and (3) mKCa and/or mKATP channels are critically involved in ramelteon-induced cardioprotection. Hearts of male Wistar rats were randomized and placed on a Langendorff system, perfused with Krebs-Henseleit buffer at a constant pressure of 80 mm Hg. All hearts were subjected to 33 minutes of global ischemia and 60 minutes of reperfusion. Before, ischemic hearts were perfused with different concentrations of ramelteon (0.01-5 μM) for determination of a concentration-effect curve. In subsequent experiments, the lowest protective concentration of ramelteon was administered together with paxilline (mKCa channel inhibitor) and 5-hydroxydecanoate (mKATP channel inhibitor). To determine whether the reduction of ischemia and reperfusion injury by ramelteon is mediated by melatonin receptor, we combined ramelteon with luzindole, a melatonin receptor antagonist. Infarct size was determined by triphenyltetrazolium chloride staining. In control animals, infarct size was 58% ± 6%. Ramelteon in a concentration of 0.03 µM reduced infarct size to 28% ± 4% (P < 0.0001 vs. Con). A lower concentration of ramelteon did not initiate cardioprotection, and higher concentrations did not further decrease infarct size. Paxilline, 5-hydroxydecanoate, and luzindole completely blocked the ramelteon-induced cardioprotection. This study shows for the first time that (1) ramelteon induces cardioprotection through melatonin receptor; (2) the effect is not concentration-dependent; and (3) activation of mKCa and mKATP channels is involved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29787401     DOI: 10.1097/FJC.0000000000000600

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  8 in total

Review 1.  Melatonin as a protective agent in cardiac ischemia-reperfusion injury: Vision/Illusion?

Authors:  Puneet Kaur Randhawa; Manish Kumar Gupta
Journal:  Eur J Pharmacol       Date:  2020-08-26       Impact factor: 4.432

2.  Activation of PKG and Akt Is Required for Cardioprotection by Ramelteon-Induced Preconditioning and Is Located Upstream of mKCa-Channels.

Authors:  Carolin Torregroza; Osameh Jalajel; Annika Raupach; Katharina Feige; Sebastian Bunte; André Heinen; Alexander Mathes; Markus W Hollmann; Ragnar Huhn; Martin Stroethoff
Journal:  Int J Mol Sci       Date:  2020-04-08       Impact factor: 5.923

Review 3.  Targeting GPCRs Against Cardiotoxicity Induced by Anticancer Treatments.

Authors:  Anais Audebrand; Laurent Désaubry; Canan G Nebigil
Journal:  Front Cardiovasc Med       Date:  2020-01-24

4.  Melatonin receptor agonist ramelteon attenuates mouse acute and chronic ischemic brain injury.

Authors:  Xiao-Li Wu; Shou-Sheng Lu; Meng-Ru Liu; Wei-Dong Tang; Jun-Zi Chen; Yan-Rong Zheng; Anil Ahsan; Ming Cao; Lei Jiang; Wei-Wei Hu; Jia-Ying Wu; Zhong Chen; Xiang-Nan Zhang
Journal:  Acta Pharmacol Sin       Date:  2020-02-27       Impact factor: 6.150

5.  Cardioprotective Properties of Mannitol-Involvement of Mitochondrial Potassium Channels.

Authors:  Katharina Feige; Janine Rubbert; Annika Raupach; Martin Stroethoff; André Heinen; Markus W Hollmann; Ragnar Huhn; Carolin Torregroza
Journal:  Int J Mol Sci       Date:  2021-02-27       Impact factor: 5.923

6.  The Melatonin Receptor Agonist Ramelteon Induces Cardioprotection that Requires MT2 Receptor Activation and Release of Reactive Oxygen Species.

Authors:  Martin Stroethoff; Lukas Goetze; Carolin Torregroza; Sebastian Bunte; Annika Raupach; André Heinen; Alexander Mathes; Markus W Hollmann; Ragnar Huhn
Journal:  Cardiovasc Drugs Ther       Date:  2020-06       Impact factor: 3.727

Review 7.  Cardioprotective Melatonin: Translating from Proof-of-Concept Studies to Therapeutic Use.

Authors:  Ovidiu Constantin Baltatu; Sergio Senar; Luciana Aparecida Campos; José Cipolla-Neto
Journal:  Int J Mol Sci       Date:  2019-09-05       Impact factor: 5.923

8.  Melatonin receptor agonist protects against acute lung injury induced by ventilator through up-regulation of IL-10 production.

Authors:  Geng-Chin Wu; Chung-Kan Peng; Wen-I Liao; Hsin-Ping Pao; Kun-Lun Huang; Shi-Jye Chu
Journal:  Respir Res       Date:  2020-03-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.